Biofeedback, Smoking Cessation
Conditions
Brief summary
The purpose of this study is to test the efficacy of two separate, sequential interventions to promote tobacco cessation/reduction in patients who are screened for lung cancer or are eligible for lung cancer screening. Each intervention will be compared to standard of care. The first intervention will be a personalized message intervention, the second intervention will consist of a biofeedback-based intervention.
Detailed description
The primary aims of this study are to test the efficacy two types of smoking cessation methods (compared to standard care). The aim of the first intervention is to evaluate the efficacy of a personalized message intervention in improving tobacco quit rates above and beyond standard care smoking cessation treatment in patients at risk for lung cancer. Messages will be designed specifically for patients at risk for lung cancer, personalized and presented in a gain-framed manner, taking into account demographics and smoking history. The aim of the second intervention is to evaluate the efficacy of a novel, biofeedback-based intervention that provides personalized individual-level feedback on biomarkers of lung cancer risk and how they improve in response to cessation, delivered in a gain-framed way. The biomarkers include skin carotenoid status, spirometry, and plasma bilirubin, all of which improve with cessation. The study team will examine whether the biofeedback prevents relapse in those who quit and leads to reductions in smoking in lung nodule patients who failed to quit. Additionally, this study will attempt to evaluate the impact of smoking cessation on miRNA profiles in human serum, especially miRNAs in the let-7 family, which are known to have tumor suppressor function, and which we hypothesize increase in response to cessation.
Interventions
BEHAVIORALpersonalized cessation care
Individuals randomized to this condition will receive standard care (i.e., 5 counseling sessions and nicotine patch(NRT)) and 4 personalized videos with 5 packages of personalized print materials
BEHAVIORALbio feedback
Individuals randomized to this group will be provided with a personalized graph of their biomarker data from baseline, 6 and 8 weeks at the 8-week and 3-month study visits.
OTHERstandard care
Sponsors
National Cancer Institute (NCI)
Yale University
Study design
Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Current Smoker. * 20 pack per year smoking history. * Eligible for the Smilow treatment program. * Willing to enroll in smoking cessation program. * Willing to be randomized in smoking cessation study. * English speaking.
Exclusion criteria
* Dementia or current serious psychiatric or unstable medical illness. * Pregnancy or breast feeding. * Known fat malabsorption diseases that may affect skin carotenoid status.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Smoking Cessation | 8 weeks | Smoking cessation will be measured by self report and validated by the study team using Carbon Monoxide (CO) levels. CO will be measured. |
| Number of cigarettes smoked | 6 months | Number of cigarettes smoked will be assessed by self report. Smoking cessation will be measured by self report and validated by the study team using Carbon Monoxide (CO) levels. CO will be measured. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Smoking Cessation | Baseline, 4 Weeks, 3 Months | Smoking cessation will be measured by self report and validated by the study team using Carbon Monoxide (CO) levels. CO will be measured. |
| Expired Air | Screening (1 week prior to baseline), Baseline, 8 Weeks, 3 Months, 6 Months | A hand held spirometer will be used to measure the volume of air expired by the lungs. |
| Skin Carotenoids | Screening (1 week prior to baseline), Baseline, 6 Weeks, 8 Weeks, 3 Months, 6 Months | Skin carotenoids are measured with a 30-second scan of the skin with visible light can be used to quantify skin carotenoids rapidly and non-invasively. This study's method sufficiently measures carotenoid status in skin as a biomarker of response to a smoking cessation intervention. |
| Plasma Bilirubin | Screening (1 week prior to baseline), 6 Weeks, 8 Weeks, 3 Months, 6 Months | 3 mls of blood will be drawn into heparinized tubes, centrifuged, and plasma transferred to opaque tubes and analyzed on the Roche DPP Modular automated chemistry analyzer at the clinical lab, using the method of Jendrassik and Grof. While indirect (unconjugated) bilirubin is likely more relevant for health effects, it is very highly correlated with total bilirubin, which is more common for physicians to test and thus more relevant for translational purposes. Thus, total bilirubin will be used for feedback. |
Countries
United States
Outcome results
None listed